CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome
| Autor: | Antonio Tugores, José María Medina-Gil, Fayna Rodríguez-González, Paloma Garay-Sánchez, Efrén Martínez-Quintana |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Genetic Markers Male 0301 basic medicine medicine.medical_specialty Acute coronary syndrome Adolescent Genotype medicine.medical_treatment Type 2 diabetes CYP2C19 030204 cardiovascular system & hematology Coronary artery disease Young Adult 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine Diabetes mellitus medicine Humans Hypoglycemic Agents Insulin Genetic Predisposition to Disease Acute Coronary Syndrome Coronary atherosclerosis Aged Aged 80 and over Polymorphism Genetic business.industry Middle Aged medicine.disease Cytochrome P-450 CYP2C19 030104 developmental biology Diabetes Mellitus Type 2 Cardiology Female business Dyslipidemia |
| Zdroj: | Medicina Clínica (English Edition). 149:235-239 |
| ISSN: | 2387-0206 |
| DOI: | 10.1016/j.medcle.2017.02.030 |
| Popis: | Introduction CYP2C19 is a major isoform of cytochrome P450 that metabolizes a number of drugs and is involved in the glucocorticoids synthesis. CYP2C19 polymorphisms have been associated with the genetic risk for type 2 diabetes. Methods Five hundred and three patients with an acute coronary event were studied to assess the association between the CYP2C19 activity ( CYP2C19 *2, CYP2C19*3 and CYP2C19 *17 variants) and the type of acute coronary syndrome, cardiovascular risk factors (arterial systemic hypertension, diabetes mellitus, dyslipidemia and smoking), analytical parameters and the extent and severity of coronary atherosclerosis. Results Genotype distribution in our series was similar to that expected in the Caucasian population. Among the traditional cardiovascular risk factors, very poor metabolizer patients (*2/*2, *3/*3 or *2/*3) had a greater tendency to present diabetes mellitus needing insulin ( p = 0.067). Conversely, when we compared very poor, poor and normal metabolizers vs. rapid and ultrarapid metabolizers we found significant differences in those diabetic patients under insulin treatment (64 patients [18%] vs. 17 patients [11%]; p = 0.032). On the contrary, analytical parameters, systemic arterial hypertension, dyslipidemia, smoking or the personal/family history of coronary artery disease did not reach statistical significance regardless of CYP2C19 activity. Similarly, the number and the type of coronary disease (thrombotic, fibrotic or both) did not differ between patients with different CYP2C19 enzyme activity. Conclusion Patients with an acute coronary event and a very poor, poor and normal CYP2C19 metabolizer genotype have a higher prevalence of diabetes mellitus needing insulin than patients with the rapid and ultrarapid metabolizers CPY2C19 genotype. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect